359 related articles for article (PubMed ID: 19376847)
1. Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease.
Liao WT; Yu CL; Lan CC; Lee CH; Chang CH; Chang LW; You HL; Yu HS
Carcinogenesis; 2009 Jun; 30(6):1064-72. PubMed ID: 19376847
[TBL] [Abstract][Full Text] [Related]
2. Arsenic carcinogenesis in the skin.
Yu HS; Liao WT; Chai CY
J Biomed Sci; 2006 Sep; 13(5):657-66. PubMed ID: 16807664
[TBL] [Abstract][Full Text] [Related]
3. Immunological dysfunction in chronic arsenic exposure: From subclinical condition to skin cancer.
Yu S; Liao WT; Lee CH; Chai CY; Yu CL; Yu HS
J Dermatol; 2018 Nov; 45(11):1271-1277. PubMed ID: 30144155
[TBL] [Abstract][Full Text] [Related]
4. Aberrant immune responses in arsenical skin cancers.
Lee CH; Liao WT; Yu HS
Kaohsiung J Med Sci; 2011 Sep; 27(9):396-401. PubMed ID: 21914527
[TBL] [Abstract][Full Text] [Related]
5. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
6. Stromal CD10 expression, as well as increased dermal macrophages and decreased Langerhans cells, are associated with malignant transformation of keratinocytes.
Takahara M; Chen S; Kido M; Takeuchi S; Uchi H; Tu Y; Moroi Y; Furue M
J Cutan Pathol; 2009 Jun; 36(6):668-74. PubMed ID: 19515046
[TBL] [Abstract][Full Text] [Related]
7. Increased chromosome aberration frequencies in the Bowen's patients compared to non-cancerous skin lesions individuals exposed to arsenic.
Ghosh P; Banerjee M; De Chaudhuri S; Das JK; Sarma N; Basu A; Giri AK
Mutat Res; 2007 Aug; 632(1-2):104-10. PubMed ID: 17600756
[TBL] [Abstract][Full Text] [Related]
8. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
[TBL] [Abstract][Full Text] [Related]
9. Effects and interactions of low doses of arsenic and UVB on keratinocyte apoptosis.
Lee CH; Yu CL; Liao WT; Kao YH; Chai CY; Chen GS; Yu HS
Chem Res Toxicol; 2004 Sep; 17(9):1199-205. PubMed ID: 15377153
[TBL] [Abstract][Full Text] [Related]
10. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
Saglam O; Salama M; Meier F; Chaffins M; Ma C; Ormsby A; Lee M
Am J Dermatopathol; 2008 Apr; 30(2):123-6. PubMed ID: 18360114
[TBL] [Abstract][Full Text] [Related]
12. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption.
Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM
Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769
[TBL] [Abstract][Full Text] [Related]
13. STAT3-dependent VEGF production from keratinocytes abrogates dendritic cell activation and migration by arsenic: a plausible regional mechanism of immunosuppression in arsenical cancers.
Hong CH; Lee CH; Chen GS; Chang KL; Yu HS
Chem Biol Interact; 2015 Feb; 227():96-103. PubMed ID: 25559853
[TBL] [Abstract][Full Text] [Related]
14. Involvement of mtDNA damage elicited by oxidative stress in the arsenical skin cancers.
Lee CH; Wu SB; Hong CH; Chen GS; Wei YH; Yu HS
J Invest Dermatol; 2013 Jul; 133(7):1890-900. PubMed ID: 23370535
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
Hsu CH; Yang SA; Wang JY; Yu HS; Lin SR
Br J Cancer; 1999 Jun; 80(7):1080-6. PubMed ID: 10362120
[TBL] [Abstract][Full Text] [Related]
16. ΔNp63 promotes abnormal epidermal proliferation in arsenical skin cancers.
Lu JH; Liao WT; Lee CH; Chang KL; Ke HL; Yu HS
Toxicol In Vitro; 2018 Dec; 53():57-66. PubMed ID: 30026126
[TBL] [Abstract][Full Text] [Related]
17. Defective IL-2 receptor expression in lymphocytes of patients with arsenic-induced Bowen's disease.
Yu HS; Chang KL; Yu CL; Wu CS; Chen GS; Ho JC
Arch Dermatol Res; 1998 Dec; 290(12):681-7. PubMed ID: 9879838
[TBL] [Abstract][Full Text] [Related]
18. Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers.
Lee CH; Wu SB; Hong CH; Liao WT; Wu CY; Chen GS; Wei YH; Yu HS
Am J Pathol; 2011 May; 178(5):2066-76. PubMed ID: 21514422
[TBL] [Abstract][Full Text] [Related]
19. P16(INK4A) expression in Bowen's disease and Bowenoid papulosis.
Auepemkiate S; Thongsuksai P; Boonyaphiphat P
J Med Assoc Thai; 2006 Sep; 89(9):1460-5. PubMed ID: 17100385
[TBL] [Abstract][Full Text] [Related]
20. [Expression of E-cadherin and beta-catenin in Bowen's disease and squamous cell carcinoma].
Li ZX; Peng ZH; Ji FP; Yuan JY; Pan M; Liu Y; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1245-7. PubMed ID: 16939929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
